FDA Approves Eli Lilly’s Taltz for Nonradiographic Axial Spondyloarthritis

Eli Lilly’s Taltz (ixekizumab) has received the FDA’s approval for treatment of active nonradiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation.

The approval was based on the results of a phase 3 trial, in which 30 percent of patients treated with 80 mg of Taltz every four weeks demonstrated improvement compared to 13 percent of patients treated with a placebo at week 52.

Taltz is the first IL-17A antagonist approved by the FDA for treatment of the disease.